Skip to main content
SpringerLink
Log in

Systemische Chemotherapie beim metastasierten Harnblasenkarzinom

  • Chapter
Book cover Therapie des Harnblasenkarzinoms

Zusammenfassung

Das metastasierte Harnblasenkarzinom stellt eine Herausforderung für den onkologisch tätigen Urologen dar. Fortschritte im Wissen um eine Verbesserung der Effektivität wurden in den letzten Jahren erzielt. So kann mit einer Responserate von mehr als 40% und mit einer Verlängerung der Dauer der Response gerechnet werden. Es bleibt jedoch immer noch unklar, welcher Patient auf diese Form der Therapie optimal reagiert, welcher nicht. Daneben muß prinzipiell mit schweren Nebenwirkungen der Zytostatika-Therapie, insbesondere deren Kombinationen, gerechnet werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 64.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Blumenreich MS, Yagoda A, Natale RB, Watson RC (1982) Phase II trial of vinblastine sulfate for metastatic urothelial tract tumors. Cancer 50:435

    Article  PubMed  CAS  Google Scholar 

  2. Carmichael J, Cornbleet MA, Mac Dougall RH et al. (1985) Cisplatin and methotrexate in treatment of transitional cell carcinoma of the urinary tract. Br J Urol 57:299

    Article  PubMed  CAS  Google Scholar 

  3. Catalona WJ, Ratliff TL, Mc Cool RE (1982) Immunology of genito-urinary tumors. In: Paulson DE (ed) Genito-urinary cancer. Vol 1 Martinus Nijhoff publishers, The Hague, Boston London, p 169

    Google Scholar 

  4. Chong C, Logothetis CJ, Dexeus FH, Sella A (1987) M-VAC on salvage chemotherapy in transitional cell carcinoma (TCC) of the urothelium previously treated with cisplatin combination therapy. Proc AACR 28:204

    Google Scholar 

  5. Cross RJ, Glashan RW, Humphrey CS, Robinson MRG, Smith PH, Williams RE (1976) Treatment of advanced bladder cancer with adriamycin and 5-fluorouracil. Br J Urol 48:609

    Article  PubMed  CAS  Google Scholar 

  6. Denis L, Niijima T, Prout G, Schroeder FH (1986) Developments in bladder cancer. Liss, New York

    Google Scholar 

  7. Harker WG, Meyers FJ, Freika FS et al. (1985) Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract; A Northern California Oncology Group Study. J Clin Oncol 3:1463

    PubMed  CAS  Google Scholar 

  8. Khandekar JD, Elson RJ, Dewijs WD, Slayton RE, Harris DT (1985) Comparative activity and toxicity of cis-diamminedichloroplatinum (DDP) and a combination of doxorubicin, cyclophosphamide and DDP in disseminated transitional cell carcinoma of the urinary tract. J Clin Oncol 3:539

    PubMed  CAS  Google Scholar 

  9. deKernion JB (1977) The chemotherapy of advanced bladder cancer. Cancer Res 37:2771

    PubMed  CAS  Google Scholar 

  10. Merrin C (1978) Efficacy of cisplatinum in genitourinary tumours. Experience in 200 cases. Biochemie 60:941

    Article  Google Scholar 

  11. Mulder JH, Fossa SD, de Pauw M, van Oosterom AT (1982) Cyclophosphamide, Adriamycin and cisplatin combination chemotherapy in advanced bladder carcinoma: an EORTC phase II study. Eur J Cancer Clin Oncol 18:111

    Google Scholar 

  12. Natale RB, Yagoda A, Watson RC, Whitemore WF, Blumenreich M, Braun DW (1981) Methotrexate: an active drug in bladder cancer. Cancer 47:1246

    Article  PubMed  CAS  Google Scholar 

  13. Oliver RTD, Kwok HK, Highman WJ, Waxman J (1986) Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer. Br J Urol 58:31

    Article  PubMed  CAS  Google Scholar 

  14. Pavone-Macaluso M, the EORTC Genito-Urinary Cooperative Group (1976) Single drug chemotherapy of bladder cancer with adriamycin, VN-26 or bleomycin. Eur Urol 2:138

    Google Scholar 

  15. Rosenberg SJ, Williams SD (1987) Cisplatinum methotrexate and vinblastin combination chemotherapy (CMV) for advanced carcinoma of the bladder and upper urinary tract. J Urol 133:157 A

    Google Scholar 

  16. Rodriguez LH, Johnson DE, Holoye PY, Samuels ML (1977) Combination VM 26 and adriamycin for metastatic transitional cell carcinoma. Cancer Treat Rep 61:87

    PubMed  CAS  Google Scholar 

  17. Rossof AH, Talley RW, Stephens R, Thigpen T, Samson MK, Groppe C, Eyre HJ, Fisher R (1979) Phase II evaluation of cisdiamminedichloroplatinum II in advanced malignancies of the genitourinary and gynaecologic organs. A Southwest Oncology Group Study. Cancer Treat Rep 63:1557

    PubMed  CAS  Google Scholar 

  18. Samuels ML (1979) CISCA combination chemotherapy. In: Johnson DE, Samuels ML (eds) 2nd Annual Conference on Cancer of the Genitourinary Tract. Raven Press, New York, p 97

    Google Scholar 

  19. Soloway MS, Ikard M, Ford K (1981) Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer. Cancer 47:476

    Article  PubMed  CAS  Google Scholar 

  20. Sternberg C, Yagoda A, Scher H, Hollander P, Watson RC, Ahmed T (1984) Methotrexate, vinblastine, adriamycin and cisplatin for transitional cell carcinoma of the urothelium. Proc Am Soc Clin Oncol 3:156

    Google Scholar 

  21. Sternberg CN, Yagoda A, Scher HT et al. (1986) Surgical staging and long time survival in patients with advanced transitional cell carcinoma (TCC) of the urothelium treated with M-VAC. Proc Am Soc Clin Oncol 5:101

    Google Scholar 

  22. Sternberg CN, Yagoda A, Scher HJ, Herr HW, Morse MJ, Sogani PC, Watson RC, Hollander PD, Whitmore Jr WF (1987) Longterm survival in advanced urothelial cancer with M-VAC: The first two years of accrual. J Urol 133:157 A

    Google Scholar 

  23. Stoter G, van Oosterom AT, Mulder JH, de Pauw M, Fossa SD (1984) Combination chemotherapy with cisplatin and VM-26 in advanced transitional cell carcinoma of the bladder. Eur J Cancer Clin Oncol 20:315

    Article  PubMed  CAS  Google Scholar 

  24. Stoter C, Splinter TAW, Child JA, Fossa D, Denis I, van Oosterom AT, de Pauw M, Sylvester R for the European Organization for Research on Treatment of Cancer Genito Urinary Group (1987) Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J Urol 137:663

    PubMed  CAS  Google Scholar 

  25. Tanseef A, Yagoda A, Needles B, Scher HI, Watson RC, Geller H (1985) Vinblastine and methotrexate for advanced bladder cancer. J Urol 13:602

    Google Scholar 

  26. Troner M, Birch R, Omura GA, Williams S (1987) Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a southeastern cancer study group trial. J Urol 137:660

    PubMed  CAS  Google Scholar 

  27. Turner AG, Hendry WE, Williams GB, Bloom HJG (1977) The treatment of advanced bladder cancer with methotrexate. Br J Urol 46:673

    Article  Google Scholar 

  28. Williams SD, Einhorn LH, Donohue JP (1979) Cisplatinum combination chemotherapy of bladder chancer. Cancer Clin Trials 2:335

    PubMed  CAS  Google Scholar 

  29. Yagoda A (1977) Future implications of phase II chemotherapy trials in ninety-five patients with measurable advanced bladder cancer. Cancer Res 37:2775

    PubMed  CAS  Google Scholar 

  30. Yagoda A, Watson RC, Grabstald H, Barzell WE, Whitmore WF (1977) Adriamycin and cyclophosphamide in advanced bladder cancer. Cancer Treat Rep 61:97

    PubMed  CAS  Google Scholar 

  31. Yagoda A, Watson RC, Whitmore WF (1979) Cisplatinum (DDP) regimens in bladder cancer. Proc Am Soc Clin Oncol 20:347

    Google Scholar 

  32. Yagoda A (1987) Chemotherapy of urothelial tract tumors. Cancer 60:574

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Urologie, Univ. Klinikum Nijmegen, Sint Radboudziekenhuis, 6500, HB-Nijmegen, Niederlande

    F. M. J. Debruyne & A. D. H. Geboers

  2. Abteilung für Onkologie, Univ. Klinikum Nijmegen, Sint Radboudziekenhuis, 6500, HB-Nijmegen, Niederlande

    P. H. M. deMulder

Authors
  1. F. M. J. Debruyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. D. H. Geboers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. H. M. deMulder
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Abteilung für Urologie der, Eberhard-Karls-Universität Tübingen, Calwer Straße 7, D-7400, Tübingen, Germany

    Karl-Horst Bichler , Stephan Heribert Flüchter  & Walter Ludwig Strohmaier ,  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1988 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Debruyne, F.M.J., Geboers, A.D.H., deMulder, P.H.M. (1988). Systemische Chemotherapie beim metastasierten Harnblasenkarzinom. In: Bichler, KH., Flüchter, S.H., Strohmaier, W.L. (eds) Therapie des Harnblasenkarzinoms. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72670-5_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-72670-5_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-72671-2

  • Online ISBN: 978-3-642-72670-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation